{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:16:41Z","timestamp":1787980601137,"version":"build-2784847793"},"reference-count":34,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.1248\/bpb.b19-00185","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T18:04:02Z","timestamp":1566237842000},"page":"1805-1813","source":"Crossref","is-referenced-by-count":4,"title":["Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells"],"prefix":"10.1248","volume":"42","author":[{"given":"Tsuyoshi","family":"Aoyama","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Shibayama","sequence":"additional","affiliation":[{"name":"Department of Drug Fomulation, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Graduate School Medical and Dental Sciences, Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Nowell PC. The minute chromosome (Ph1) in chronic granulocytic leukemia. Ann. Hematol.<\/i>, 8<\/b>, 65\u201366 (1962).","DOI":"10.1007\/BF01630378"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature<\/i>, 243<\/b>, 290\u2013293 (1973).","DOI":"10.1038\/243290a0"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer<\/i>, 5<\/b>, 172\u2013183 (2005).","DOI":"10.1038\/nrc1567"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev.<\/i>, 18<\/b>, 459\u2013471 (2007).","DOI":"10.1016\/j.cytogfr.2007.06.015"},{"key":"5","unstructured":"5) Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood<\/i>, 111<\/b>, 4022\u20134028 (2008)."},{"key":"6","unstructured":"6) Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Ohtake S, Naoe T. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: The JALSG CML202 study. Cancer Sci.<\/i>, 103<\/b>, 1071\u20131078 (2012)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chen TC, Chen LC, Huang YB, Chang CS. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int. J. Clin. Pharm.<\/i>, 36<\/b>, 172\u2013181 (2014).","DOI":"10.1007\/s11096-013-9876-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) J\u00f6nsson S, Olsson B, S\u00f6derberg J, Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study. Ann. Hematol.<\/i>, 91<\/b>, 679\u2013685 (2012).","DOI":"10.1007\/s00277-011-1359-0"},{"key":"9","unstructured":"9) Fujisawa S, Ueda Y, Usuki K, et al.<\/i> Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int. J. Clin. Oncol.<\/i>, 24<\/b>, 445\u2013453 (2018)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Okada M, Imagawa J, Tanaka H, et al.<\/i> Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin. Lymphoma<\/i>. Myeloma Leuk.<\/i>, 18<\/b>, 353\u2013360.e1 (2018).","DOI":"10.1016\/j.clml.2018.03.004"},{"key":"11","unstructured":"11) Rea D, Nicolini FE, Tulliez M, Guilhot J, Gardembas M, Villemagne B, Escoffre-barbe M, Ianotto J, Charbonnier A, Johnson-ansah H. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood<\/i>, 129<\/b>, 846\u2013855 (2016)."},{"key":"12","unstructured":"12) Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O\u2019Brien SG, Coffey T, Foroni L, Copland M. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol.<\/i>, 4<\/b>, e310\u2013e316 (2017)."},{"key":"13","unstructured":"13) Heged\u0171s C, \u00d6zvegy-Laczka C, Ap\u00e1ti A\u00c1, Mag\u00f3csi M, N\u00e9met K, Orfi L, K\u00e9ri G, Katona M, Tak\u00e1ts Z, V\u00e1radi A, Szak\u00e1cs G, Sarkadi B. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: Implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol.<\/i>, 158<\/b>, 1153\u20131164 (2009)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells. Biol. Pharm. Bull.<\/i>, 37<\/b>, 1330\u20131335 (2014).","DOI":"10.1248\/bpb.b14-00254"},{"key":"15","unstructured":"15) Gromicho M, Dinis J, Magalh\u00e3es M, Fernandes AR, Tavares P, Laires A, Rueff J, Rodrigues AS. Development of imatinib and dasatinib resistance: Dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk. Lymphoma<\/i>, 52<\/b>, 1980\u20131990 (2011)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia<\/i>, 31<\/b>, 75\u201382 (2017).","DOI":"10.1038\/leu.2016.179"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lardo M, Castro M, Moiraghi B, Rojas F, Borda N, Rey JA, Lazarowski A. MDR1\/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Res.<\/i>, 50<\/b>, 154\u2013159 (2015).","DOI":"10.5045\/br.2015.50.3.154"},{"key":"18","unstructured":"18) Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs.<\/i> imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia<\/i>, 26<\/b>, 2197\u20132203 (2012)."},{"key":"19","unstructured":"19) Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nilotinib vs.<\/i> imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int. J. Hematol.<\/i>, 107<\/b>, 327\u2013336 (2018)."},{"key":"20","unstructured":"20) Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Ohashi K, Li L, Miyoshi M. Dasatinib versus<\/i> imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int. J. Hematol.<\/i>, 105<\/b>, 792\u2013804 (2017)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon F. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood<\/i>, 109<\/b>, 3496\u20133499 (2009).","DOI":"10.1182\/blood-2006-07-036012"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Takahashi N, Wakita H, Miura M, Scott SA, Nishii K, Masuko M, Sakai M, Maeda Y, Ishige K, Kashimura M, Fujikawa K, Fukazawa M, Katayama T, Monma F, Narita M, Urase F, Furukawa T, Miyazaki Y, Katayama N, Sawada K. Correlation between imatinib pharmacokinetics and clinical response in japanese patients with chronic-phase chronic myeloid leukemia. Clin. Pharmacol. Ther.<\/i>, 88<\/b>, 809\u2013813 (2010).","DOI":"10.1038\/clpt.2010.186"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J.<\/i>, 17<\/b>, 2160\u20132162 (2003).","DOI":"10.1096\/fj.03-0322"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Larson RA, Yin OQP, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, Le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur. J. Clin. Pharmacol.<\/i>, 68<\/b>, 723\u2013733 (2012).","DOI":"10.1007\/s00228-011-1200-7"},{"key":"25","unstructured":"25) Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: Retrospective exposure-response analysis of a phase III study. Clin. Pharmacol. Adv. Appl.<\/i>, 5<\/b>, 85\u201397 (2013)."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus<\/i> imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.<\/i>, 362<\/b>, 2260\u20132270 (2010).","DOI":"10.1056\/NEJMoa1002315"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ciarcia R, Damiano S, Puzio MV, Montagnaro S, Pagnini F, Pacilio C, Caparrotti G, Bellan C, Garofano T, Polito MS, Giordano A, Florio S. Comparison of dasatinib, nilotinib, and imatinib in the treatment of chronic myeloid leukemia. J. Cell. Physiol.<\/i>, 231<\/b>, 680\u2013687 (2016).","DOI":"10.1002\/jcp.25118"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, Smykla R, Lee FY, Vakkila J, Jalkanen S, Salmi M, Porkka K. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia<\/i>, 27<\/b>, 914\u2013924 (2013).","DOI":"10.1038\/leu.2012.348"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Iriyama N, Hatta Y, Takei M. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes. Cancer Med.<\/i>, 5<\/b>, 3223\u20133234 (2016).","DOI":"10.1002\/cam4.925"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Vainstein V, Eide CA, Hare TO, Shukron O, Druker BJ. Integrating in vitro<\/i> sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood<\/i>, 122<\/b>, 3331\u20133335 (2013).","DOI":"10.1182\/blood-2012-08-452409"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab. Dispos.<\/i>, 38<\/b>, 1371\u20131380 (2010).","DOI":"10.1124\/dmd.109.031302"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, J\u00f8rgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia<\/i>, 23<\/b>, 1999\u20132006 (2009).","DOI":"10.1038\/leu.2009.166"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Xing H, Liu T, Meng W, Gong Y. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib. Int. J. Lab. Hematol.<\/i>, 33<\/b>, 176\u2013181 (2011).","DOI":"10.1111\/j.1751-553X.2010.01267.x"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Che XF, Nakajima Y, Sumizawa T, Ikeda R, Ren XQ, Zheng CL, Mukai M, Furukawa T, Haraguchi M, Gao H, Sugimoto Y, Akiyama S. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett.<\/i>, 187<\/b>, 111\u2013119 (2002).","DOI":"10.1016\/S0304-3835(02)00359-2"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/11\/42_b19-00185\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T23:21:03Z","timestamp":1572650463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/11\/42_b19-00185\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00185","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}